GlassScriptPhysician profile
Sorel Lira
NPI 1639445331
$1,052.63
in general payments reported to CMS, 2019-2025
17 companies · $33.51 in 2025
The $33.51 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $124 · 2021: $197 · 2022: $159 · 2023: $222 · 2024: $178 · 2025: $33.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $243.71 | 2019-2024 | Xarelto |
| Vifor Pharma, INC. | $165.04 | 2019-2023 | Veltassa |
| Pfizer INC. | $91.46 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $74.07 | 2020-2024 | |
| Gilead Sciences, INC. | $62.97 | 2022-2024 | Veklury |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.23 | 2020-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $52.06 | 2021-2023 | Dificid, Zerbaxa, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.14 | 2023-2024 | Xifaxan |
| Abbvie INC. | $44.61 | 2021-2024 | |
| Mylan Specialty L.P. | $40.01 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $38.28 | 2023-2024 | Andexxa |
| E.R. Squibb & Sons, L.L.C. | $34.20 | 2020-2021 | |
| Allergan, INC. | $24.00 | 2020 | |
| Paratek Pharmaceuticals, INC. | $22.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.30 | 2023 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $19.49 | 2023 | Rebyota |
| Vapotherm INC | $17.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sorel Lira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.